- **Telomir Pharmaceuticals, Inc.** announced new findings on **October 8, 2025**, demonstrating that its compound, **Telomir-1**, significantly reduces the survival of aggressive **triple-negative breast cancer (TNBC) cells** in laboratory studies.  **[1971532_0001493152-25-017422_form8-k.htm:1]** 
- The discovery indicates that Telomir-1 **shuts down cellular energy pathways and mitochondrial function** in aggressive breast cancer cells, leading to cell death through **iron-dependent regulation**.  **[1971532_0001493152-25-017422_form8-k.htm:1]** 
- This mechanism is particularly relevant as aggressive cancer cells are highly dependent on iron, suggesting Telomir-1 may **selectively target cancer cells** while potentially sparing healthy tissue.  **[1971532_0001493152-25-017422_form8-k.htm:1]** 
- The company plans to **expand these studies** to include additional cancer types, such as pancreatic and leukemia models, and conduct further animal studies in preparation for an **Investigational New Drug (IND) submission**.  **[1971532_0001493152-25-017422_form8-k.htm:1]**

Telomir Pharmaceuticals (TELO)